Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 2011

View Archived Issues

Selective SYK inhibitors P505-15 and P459-72 show anticancer potential

Anti-HIV-1 activity of aciclovir and potentiation by ribavirin

Tekmira Pharma begins phase I trial of TKM-080301 in solid tumors

New antagonists of melanin-concentrating hormone MCH1 receptor claimed

Apricus Biosciences grants Bracco rights to market Vitaros in Italy

New CGRP receptor antagonists identified by Boehringer Ingelheim

Phase II trial evaluates CK-2017357 in generalized myasthenia gravis

New antagonists of voltage-gated potassium channels claimed by Xention

FDA approves generic version of Doryx

Vascular Biogenics begins phase II trials of VB-111 in glioblastoma and thyroid cancer

Novartis researchers claim novel PI3K and mTOR inhibitors

BioCryst Pharma begins phase IIb trial of BCX-4208 as add-on therapy for gout

Advanced Cell Technology enters stock purchase agreement with Socius

BioSante raises funds for phase III LibiGel program

Phase II data presented on AIC-246 for human cytomegalovirus infection

Cumberland Pharma voluntarily recalls six lots of Acetadote in U.S.

IMMU-114 shows potential for treating GVHD

Lundbeck completes two phase III trials of nalmefene for alcohol dependence

McKesson acquires US Oncology

BL-5010 is efficacious in nonsurgical removal of skin lesions in phase I/II trial

Proteome Sciences and Janssen Pharmaceutica enter into collaboration

MK-2461 is active in model of multiple myeloma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...